TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Tiziana Life Sciences ( (TLSA) ) is now available.
On November 25, 2025, Tiziana Life Sciences announced that its Phase 2 clinical trial for intranasal foralumab in amyotrophic lateral sclerosis (ALS) patients has been accepted into the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS at Mass General Brigham. This inclusion marks a significant step in the company’s efforts to advance its innovative treatment, which aims to modulate the immune system to slow ALS progression. The trial is supported by the ALS Association and will be conducted at multiple U.S. centers within the NEALS Consortium. The acceptance into the ALS MyMatch Program enhances Tiziana’s positioning in the biotechnology industry, potentially paving the way for future clinical advancements and offering hope for ALS patients.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies. The company specializes in immunotherapy, with a particular emphasis on intranasal delivery methods, which aim to improve efficacy, safety, and tolerability compared to traditional intravenous routes. Tiziana’s lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody currently in clinical development.
Average Trading Volume: 314,800
Technical Sentiment Signal: Buy
Current Market Cap: $192.8M
See more data about TLSA stock on TipRanks’ Stock Analysis page.